期刊文献+

磷酸西格列汀联合二甲双胍治疗2型糖尿病的临床疗效研究 被引量:9

下载PDF
导出
摘要 目的分析对2型糖尿病患者予以二甲双胍、磷酸西格列汀联合治疗的具体效果。方法选择2016年1月至2018年1月于我院接受治疗的2型糖尿病患者74例,采用奇偶法将其分为观察组(37例患者行磷酸西格列汀联合二甲双胍治疗)与对照组(37例患者行二甲双胍治疗),对比2组患者治疗后生化指标、体质量指数和临床治疗效果。结果观察组患者的空腹血糖、餐后2 h血糖、糖化血红蛋白、体质量指数、血脂总胆固醇均优于对照组,存在统计学意义(P<0.05)。与对照组治疗的总有效率对比(83.78%),观察组患者的治疗有效率(97.29%)更高,存在统计学意义(P<0.05)。结论二甲双胍、磷酸西格列汀联合治疗模式在2型糖尿病患者治疗方面效果显著,可以有效控制患者空腹血糖、餐后2 h血糖及糖化血红蛋白情况,安全性高,值得予以临床推广。
作者 常昕昱
出处 《中国医药指南》 2019年第14期145-146,共2页 Guide of China Medicine
  • 相关文献

参考文献6

二级参考文献41

  • 1Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide,a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monothe~apy or added to metformin,is primarily as a result of a reduction in fat tissue [J]. Diabetes Obes Metab, 2009,11 (12) : 1163- 1172.
  • 2Tremblay AJ,Lamarche B,Lemelin N,et al. Effect of sitagliptin therapy on postprandial lipoprotein level in patient with type 2 diabetes [J]. Diabetes Obes Metab,2011,13 (4) : 366-373.
  • 3Ross SA,Rafeiro E, Meinicke T,et al. Efficacy and safety of Linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin : a randomized, double-blind, placebo-controlled trial [J]. Curt Med Res Opin,2012,28(9): 1465-1474.
  • 4Blonde L,Dagogo-Jaek S,Banerji MA,et al. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin:resuhs of the Galiant Trial : a primary care,type 2 diabetes study [J]. Diabetes Obes Metab, 2009,11 (10) : 978-986.
  • 5Matthews DR, Dejager S,Ahren B, et al. Vildagliptin add on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride,with no weight gain:results from a 2 year study [J]. Diabetes Obes Metab,2010,12(9) :780-789.
  • 6Mohan V, Yang W, Son HY , et al. Efficacy and safety of Sitagliptin in the treatment of patients with type 2 diabetes in China,India,and Korea [J]. Diabetes Res Clin Pract, 2009,83 ( 1 ) : 106-116.
  • 7Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase -4 inhibitor, Sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin [J]. Diabetes Obes Metab,2007,9(5):733-745.
  • 8Aschner P,Katzeff HL,Guo H,et al. Efficacy and safety of monotherapy of Sitagliptin compared with mefformin in patients with type 2 diabetes [J]. Diabetes Obes Metab, 2010,12(3) : 252-261.
  • 9Garber A,Henry R,Ratner R,et al. LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes(LEAD-3Mono) :a randomized,52-week, phsae III ,double-blinded,parallel treatment trial [J]. Lancet, 2009,373 (9662) : 473-481.
  • 10DeFronzo RA, Hissa MN, Garber AJ,et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone [J]. Diabetes Care,2009, 32(9) : 1649-1655.

同被引文献55

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部